Ipsen Company Profile
✉ Email this page to a colleague
What is the competitive landscape for IPSEN, and what generic alternatives to IPSEN drugs are available?
IPSEN has five approved drugs.
There are forty-four US patents protecting IPSEN drugs.
There are three hundred and sixty-two patent family members on IPSEN drugs in forty-nine countries and twenty-seven supplementary protection certificates in fifteen countries.
Drugs and US Patents for Ipsen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | RX | Yes | No | 10,093,697 | ⤷ Subscribe | ⤷ Subscribe | ||||
Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | RX | Yes | No | 10,011,633 | ⤷ Subscribe | ⤷ Subscribe | ||||
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
Ipsen | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,364,473 | ⤷ Subscribe | ⤷ Subscribe | ||||
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-002 | Aug 16, 2023 | RX | Yes | No | 10,292,954 | ⤷ Subscribe | ⤷ Subscribe | ||||
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-005 | Aug 16, 2023 | RX | Yes | Yes | 9,789,074 | ⤷ Subscribe | ⤷ Subscribe | ||||
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-005 | Aug 16, 2023 | RX | Yes | Yes | 11,622,959 | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ipsen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | 7,132,416 | ⤷ Subscribe |
Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | 7,132,416 | ⤷ Subscribe |
Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | 7,132,416 | ⤷ Subscribe |
Ipsen | IQIRVO | elafibranor | TABLET;ORAL | 218860-001 | Jun 10, 2024 | 7,943,661 | ⤷ Subscribe |
Ipsen | IQIRVO | elafibranor | TABLET;ORAL | 218860-001 | Jun 10, 2024 | 7,632,870 | ⤷ Subscribe |
Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-003 | Aug 30, 2007 | 5,595,760 | ⤷ Subscribe |
Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-002 | Aug 30, 2007 | 5,595,760 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Ipsen Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Brazil | PI0312398 | ⤷ Subscribe |
China | 111773213 | ⤷ Subscribe |
Japan | 7463329 | ⤷ Subscribe |
Lithuania | 3400944 | ⤷ Subscribe |
Mexico | 338535 | ⤷ Subscribe |
Portugal | 3337478 | ⤷ Subscribe |
Taiwan | 201412345 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ipsen Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1746976 | 1790033-3 | Sweden | ⤷ Subscribe | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT.; REG. NO/DATE: EU/1/16/1130 20161008 |
1746976 | 17C1027 | France | ⤷ Subscribe | PRODUCT NAME: SEL DE SUCROSOFATE D'IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
3400944 | 2021C/554 | Belgium | ⤷ Subscribe | PRODUCT NAME: ODEVIXIBAT; AUTHORISATION NUMBER AND DATE: EU/1/21/1566 20210719 |
3400944 | 301157 | Netherlands | ⤷ Subscribe | PRODUCT NAME: ODEVIXIBAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1566 20210719 |
3400944 | CA 2022 00001 | Denmark | ⤷ Subscribe | PRODUCT NAME: ODEVIXIBAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1566 20210719 |
3400944 | CR 2022 00001 | Denmark | ⤷ Subscribe | PRODUCT NAME: ODEVIXIBAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1566 20210719 |
0137145 | SPC/GB97/010 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.